Evolus EOLS 深 沪
已收盘 02-06 16:00:00 美东时间
4.50
+0.090
+2.04%
华盛通- 最 高4.60
- 今 开4.50
- 成交量 88.30万股
- 最 低 4.46
- 昨 收 4.41
- 总市值 2.92亿
- 52周最高 15.06
- 市盈率 静 --
- 换手率 1.36%
- 52周最低 4.405
- 委 比 -77.50%
- 总股本 6481.98万
- 历史最高 39.50
- 量 比 0.81
- 振 幅 3.17%
- 历史最低 2.85
- 每 手 1
- 风险率 2.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs Feb 4 (Reuters) - AbbVie ABBV.N forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong demand for newer immunology drugs Skyrizi and Rinvoq and
02-04 20:48
美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元
02-04 12:15
HC Wainwright & Co. Maintains Buy on Evolus, Lowers Price Target to $13
HC Wainwright & Co. analyst Douglas Tsao maintains Evolus (NASDAQ:EOLS) with a Buy and lowers the price target from $20 to $13.
02-03 20:16
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
BTIG Maintains Buy on Evolus, Lowers Price Target to $13
BTIG analyst Sam Eiber maintains Evolus (NASDAQ:EOLS) with a Buy and lowers the price target from $18 to $13.
01-22 17:51
U.S. RESEARCH ROUNDUP-Cencora, Crocs, Teledyne Technologies
U.S. RESEARCH ROUNDUP-Cencora, Crocs, Teledyne Technologies Jan 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cencora, Crocs and Teledyne Technologies, on Thursday. HIGHLIGHTS * Cencora COR.N : Jefferies raises to b
01-22 15:17
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
AEON Biopharma announced two positive developments: a successful BPD Type 2a meeting with the FDA and shareholder approval of November transactions, including PIPE financing and Daewoong note exchange. These events strengthen AEON's financial position and advance ABP-450's biosimilar development.
01-21 21:05
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $20 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $20 price target.
01-10 01:35
